Merck & Co., Inc. $MRK Stock Purchased by Vise Technologies Inc.

Vise Technologies Inc. raised its position in Merck & Co., Inc. (NYSE:MRK) by 32.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 289,347 shares of the company’s stock after purchasing an additional 71,528 shares during the period. Vise Technologies Inc.’s holdings in Merck & Co., Inc. were worth $42,045,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. Dimensional Fund Advisors LP boosted its stake in shares of Merck & Co., Inc. by 23.8% during the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock worth $1,858,938,000 after buying an additional 2,969,856 shares during the period. Bank of America Corp DE boosted its holdings in Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after purchasing an additional 2,919,780 shares in the last quarter. Assenagon Asset Management S.A. raised its position in Merck & Co., Inc. by 263.7% in the second quarter. Assenagon Asset Management S.A. now owns 2,702,992 shares of the company’s stock worth $347,334,000 after acquiring an additional 1,959,778 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after acquiring an additional 1,934,312 shares during the period. Finally, SEB Asset Management AB acquired a new position in shares of Merck & Co., Inc. during the 1st quarter worth $197,550,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. BMO Capital Markets lifted their price target on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, August 20th. UBS Group lifted their price target on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Wells Fargo & Company increased their price target on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday, September 4th. Citigroup lifted their price objective on Merck & Co., Inc. from $125.00 to $145.00 and gave the company a “neutral” rating in a research note on Monday, October 12th. Finally, Scotiabank increased their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, September 29th. Seventeen analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $156.08.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Strong Q3 results and raised outlook: Merck reported adjusted earnings of $2.49 per share versus the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, ahead of estimates. Management raised its 2026 sales and adjusted-profit outlook, providing the main catalyst for the stock’s advance. Merck tops quarterly estimates and hikes profit outlook
• Positive Sentiment: Growth beyond Keytruda: Keytruda, including the newer Qlex formulation, delivered stronger-than-expected sales, while WINREVAIR continued to expand rapidly. Newer product launches are helping offset losses from generic competition and support Merck’s growth outlook. Merck Q3 earnings call highlights pipeline progress and raised outlook
• Positive Sentiment: Pipeline progress: Positive Phase 3 endometrial-cancer data for Keytruda and sacituzumab tirumotecan, along with FDA priority review for the latter, strengthens confidence in Merck’s oncology pipeline and its ability to address future revenue pressure. Merck Phase 3 endometrial cancer data and FDA review
• Positive Sentiment: Supportive analyst action: Guggenheim raised its price target to $171 and maintained a buy rating, indicating additional potential upside based on the earnings and pipeline outlook.

Insider Buying and Selling

In other news, EVP Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the transaction, the executive vice president owned 36,613 shares of the company’s stock, valued at $4,942,755. The trade was a 21.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 228,238 shares of company stock worth $29,977,783 in the last ninety days. Insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Trading Up 2.3%

NYSE:MRK opened at $149.75 on Friday. The firm has a market capitalization of $369.46 billion, a P/E ratio of 154.38, a P/E/G ratio of 6.52 and a beta of 0.21. The business has a 50 day simple moving average of $146.90 and a 200 day simple moving average of $126.69. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.09 by $0.40. The business had revenue of $18.09 billion during the quarter, compared to the consensus estimate of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.56% and a net margin of 3.64%. The business’s revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.58 earnings per share. Equities research analysts predict that Merck & Co., Inc. will post 2.81 EPS for the current year.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.